Chemotherapy: A new standard combination for recurrent ovarian cancer?

Nature Reviews Clinical Oncology

Volumn 7, Issue 10, 2010, Pages 559-560

  Bast Jr , Robert C ^a   Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMMUNOGLOBULIN E ANTIBODY; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN; TRABECTEDIN;

ALOPECIA; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HAND FOOT SYNDROME; HUMAN; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SHORT SURVEY; T CELL LYMPHOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; SURVIVAL RATE;

EID: 77957555120     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.152     Document Type: Short Survey

References (10)

1. Parmer, M. K. et al. Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO/OVAR-2.2 trial. Lancet 361, 2099-2106 (2003).
2. Pfisterer, J. et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24, 4699-4707 (2006).
3. Pujade-Lauraine, E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323-3329 (2010).
4. Markman, M. et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol. Oncol. 116, 323-325 (2010).
5. Syrigou, E., Makrilia, N., Koti, I., Saif, M. W. & Syrigos, K. N. Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs 20, 1-6 (2009).
6. Vecchi, A., Mantovani, A., Tagliabue, A. & Spreafico, F. A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection. Cancer Res. 36, 1222-1227 (1976).
7. Ehrke, M. J., Tomazic, V., Ryoyama, K., Cohen, S. A. & Mihich, E. Adriamycin induced immunomodulation: dependence upon time of administration. Int. J. Immunopharmacol. 5, 43-48 (1983).
8. Monk, B. J. et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28, 3107-3114 (2010).
9. Cannistra, S. A. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J. Clin. Oncol. 28, 3101-3103 (2010).
10. Bast, R. C. et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol. Oncol. 107, 173-176 (2007).